Novartis touts U.S. filing plans for MS drug as patent losses loom

ZURICH (Reuters) - Novartis plans to file its BAF312 multiple sclerosis drug for U.S. approval within weeks, the Swiss drugmaker said on Friday, as it seeks to refresh its portfolio of neurological medicines that is about to be hit by patent losses.

from Reuters: Health News http://ift.tt/2G5m6Lg